M
Marianna Lucafò
Researcher at University of Trieste
Publications - 57
Citations - 768
Marianna Lucafò is an academic researcher from University of Trieste. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 13, co-authored 51 publications receiving 534 citations. Previous affiliations of Marianna Lucafò include IRCCS Materno Infantile Burlo Garofolo.
Papers
More filters
Journal ArticleDOI
New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles
Nelly Mezzaroba,Sonia Zorzet,Erika Secco,Stefania Biffi,Claudio Tripodo,Marco Calvaruso,Ramiro Mendoza-Maldonado,Sara Capolla,Marilena Granzotto,Ruben Spretz,Gustavo Larsen,Sandra Noriega,Marianna Lucafò,Eduardo Mansilla,Chiara Garrovo,Gustavo Horacio Marín,Gabriele Baj,Valter Gattei,Gabriele Pozzato,Luis Nunez,Paolo Macor +20 more
TL;DR: Light is shed on the potential of anti-CD20 nanoparticles carrying Hydroxychloroquine and Chlorambucil for controlling a disseminated model of aggressive lymphoma, and credence is lent to the idea of adopting this therapeutic approach for the treatment of B-cell disorders.
Journal ArticleDOI
The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients.
Ester Pagano,Barbara Romano,Fabio Arturo Iannotti,Olga A. Parisi,Maria D'Armiento,S. Pignatiello,Lorena Coretti,Marianna Lucafò,Tommaso Venneri,Gabriele Stocco,Francesca Lembo,Pierangelo Orlando,Raffaele Capasso,V. Di Marzo,Angelo A. Izzo,Francesca Borrelli +15 more
TL;DR: CBDV exerts intestinal anti-inflammatory effects in mice via TRPA1, and in children with active UC, and has a favorable safety profile in humans, which may be considered for possible clinical trials in patients with UC.
Journal ArticleDOI
Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study
Samuele Naviglio,Doriana Lacorte,Marianna Lucafò,Adriana Cifù,Diego Favretto,Eva Cuzzoni,Tania Silvestri,Martina Pozzi Mucelli,Oriano Radillo,Giuliana Decorti,Martina Fabris,Matteo Bramuzzo,Andrea Taddio,Gabriele Stocco,Patrizia Alvisi,Alessandro Ventura,Stefano Martelossi +16 more
TL;DR: Most cases of therapeutic failure were associated with low serum drug levels, and IFX trough levels at the end of induction are associated with sustained long-term response.
Journal ArticleDOI
Study of a potential drug delivery system based on carbon nanoparticles: effects of fullerene derivatives in MCF7 mammary carcinoma cells
Marianna Lucafò,Sabrina Pacor,Chiara Fabbro,Tatiana Da Ros,Sonia Zorzet,Maurizio Prato,Gianni Sava +6 more
TL;DR: A strong interaction between the tested fullerene and mammalian cells and a significant ability of this compound to enter tumor cells are suggested, therefore resulting to be a suitable vector to deliver anticancer agents to tumor cells.
Journal ArticleDOI
Long noncoding RNA GAS5: a novel marker involved in glucocorticoid response.
Marianna Lucafò,S. De Iudicibus,A. Di Silvestre,Marco Pelin,Luigi Candussio,Stefano Martelossi,Alberto Tommasini,Elisa Piscianz,Alessandro Ventura,Giuliana Decorti +9 more
TL;DR: It is suggested that abnormal levels of GAS5 may alter GC effectiveness, probably interfering with the mechanism of GR autoregulation.